EU-Humira ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 46 | Malignant rheumatoid arthritis | 1 |
46. Malignant rheumatoid arthritis
Clinical trials : 4,325 / Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03052322 (ClinicalTrials.gov) | January 31, 2017 | 29/1/2017 | MSB11022 in Moderate to Severe Rheumatoid Arthritis | A Multicenter, Randomized, Double-blind, Phase III Trial to Evaluate the Safety, Immunogenicity, and Efficacy of MSB11022 Compared With Humira® in Patients With Moderately to Severely Active Rheumatoid Arthritis | Moderate to Severe Rheumatoid Arthritis | Drug: MSB11022;Drug: EU-Humira | Fresenius Kabi SwissBioSim GmbH | NULL | Completed | 18 Years | N/A | All | 288 | Phase 3 | Bulgaria;Czechia;Germany;Hungary;Poland;United Kingdom;Czech Republic |